Collegium Pharmaceutical Inc. (COLL) Trading Up 6.2%
Collegium Pharmaceutical Inc. (NASDAQ:COLL) shares were up 6.2% on Wednesday . The stock traded as high as $12.24 and last traded at $12.24, with a volume of 58,363 shares trading hands. The stock had previously closed at $11.53.
Several research analysts have weighed in on COLL shares. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price target (up from $28.00) on shares of Collegium Pharmaceutical in a report on Thursday, May 26th. Piper Jaffray Cos. reiterated a “buy” rating and issued a $27.00 price target (up from $26.00) on shares of Collegium Pharmaceutical in a report on Thursday, June 23rd. Finally, Zacks Investment Research upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $29.25.
The stock’s 50 day moving average is $12.60 and its 200 day moving average is $16.29. The company’s market capitalization is $279.27 million.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.08. Equities analysts predict that Collegium Pharmaceutical Inc. will post ($3.25) earnings per share for the current fiscal year.
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.